GPC Completes Satraplatin Rolling NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Company is requesting priority review for use of the novel oral platinum drug in second-line hormone refractory prostate cancer.
You may also be interested in...
GPC Retrenches While Awaiting Satraplatin Data
German firm cuts 46 U.S. positions while “retaining core commercialization teams” in anticipation of oncologic’s eventual approval.
GPC Retrenches While Awaiting Satraplatin Data
German firm cuts 46 U.S. positions while “retaining core commercialization teams” in anticipation of oncologic’s eventual approval.
GPC Biotech Aims To Bring Satraplatin To Market This Year
Potential partners for the prostate cancer compound are “inundating” the company with offers, CEO tells BIO CEO & Investor Forum in New York.